|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net (loss) income | |||||
| Non-cash adjustments to reconcile net (loss) income to net cash used in operating activities: | |||||
| Stock-based compensation expense | |||||
| Acquired in-process research and development | |||||
| Depreciation | |||||
| Amortization and accretion, net | |||||
| Change in fair value of warrant liability | |||||
| Provision for inventory reserve | |||||
| Depreciation and amortization expense | |||||
| Accretion on investments, net of amortization | |||||
| Other non-cash items | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Inventories | |||||
| Prepaid expenses and other assets | |||||
| Donation of equipment | |||||
| Accounts payable and accrued liabilities | |||||
| Operating right-of-use assets and lease liabilities, net | |||||
| Contract liability | |||||
| Net cash and cash equivalents (used in) provided by operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchases of short-term investments, available-for-sale | |||||
| Maturities of short-term investments, available-for-sale | |||||
| Payments of milestone obligations under license agreements | |||||
| Purchases of property and equipment | |||||
| Net cash and cash equivalents provided by (used in) investing activities | |||||
| Cash flows from financing activities: | |||||
| Cash proceeds from the Merger, net of transaction costs | |||||
| Financing liability | |||||
| Proceeds from term loan, net of issuance costs | |||||
| Proceeds from exercise of common stock options and issuance of common stock under the employee stock purchase plan | |||||
| Repayment of bank note payable | |||||
| Proceeds from milestone obligations met under license agreements recognized as an increase to the financing liability | |||||
| Net cash and cash equivalents provided by financing activities | |||||
| Net decrease in cash and cash equivalents | |||||
| Cash and cash equivalents at beginning of period | |||||
| Cash and cash equivalents at end of period | |||||
| Conversion of Series A, B, C, and D convertible preferred stock to common stock | |||||
| Short-term investments assumed in the Merger | |||||
| Removal of retrospective insurance policy acquired in the Merger, included in prepaid and other current assets and other assets, and related reduction in additional paid in capital | |||||
| Stock-based compensation capitalized into inventory | |||||
| Purchases of inventories included in accounts payable | |||||
| Prepaid expense and other current assets assumed in the Merger | |||||
| Accounts payable and accrued liabilities assumed in the Merger | |||||
| Reclassification of warrant liability to equity | |||||
| Interest paid | |||||
| Purchases of property and equipment included in accounts payable | |||||
| Purchases of property and equipment reclassed from prepaid expenses and other current assets | |||||
| Supplemental cash flow information: | |||||
| Cash paid for interest | |||||
Loading...